Full Press Release Details
Near-Term Milestones Timetable for 2014/2015
TIKVA, Israel, November 18, 2014 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing
a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced several upcoming
and near-term milestones on its CF101 and CF102 indications for liver cancer, rheumatoid arthritis, psoriasis, glaucoma and the
development of a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).
Company believes that it is on the cusp of reaching several significant milestones in its studies, with respect to CF102 for the
treatment liver cancer and CF101 with respect to the treatment of rheumatoid arthritis, psoriasis and glaucoma. The below near-term
key events provide an outlook of Can-Fite's objectives and potential for increased growth.
Milestones for 2014/2015:
| Q4 2014 - Planning Phase III trials for rheumatoid arthritis following the release of positive Phase II study results. | ||
| Q1 2015 - Announce data for Phase II/III trial for psoriasis with 300 patients for which Can-Fite has already received positive interim data from the first 100 patients . | ||
| Q2/Q3 2015 - Announce data for the Phase II study for glaucoma with 88 patients. |
| Q4 2014 - A3AR predictive biomarker blood test kit which will have commercial applications. The commercial kit is designed to be used prior to treatment to help identify an individual patient's responsiveness to the Company's drugs, providing more personalized medicine. | ||
| The U.S. Patent and Trademark Office previously issued a patent for the utilization of A3AR as a biomarker to predict patient response to CF101 in autoimmune inflammatory indications. |
are very excited at the opportunity of potentially receiving further validation on our drug candidates which represents significant
steps forward in our commitment to delivering treatments to patients. We hope to see this come to fruition upon conclusion of
our psoriasis, liver cancer and glaucoma trials." stated Can-Fite CEO Dr. Pnina Fishman.
leading proprietary compounds, CF101 and CF102, are centered on multi-billion dollar market opportunities. According to GlobalData,
the psoriasis drug market is forecasted to grow from $3.6 billion in 2010 to $6.7 billion by 2018, while the rheumatoid arthritis
drug market according to independent business information provider visiongain, is predicted to generate revenues of $38.5 billion
by 2017. GIA projects that the global liver cancer drugs market will exceed $2 billion by 2015 and GlobalData projects that the
glaucoma market to top $3 billion by 2018.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's
CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid
arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation
by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon,
prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies
to date. For more information, please visit: www.can-fite.com
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other
things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition,
from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other variations of these
words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities
and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive
officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject
to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially
from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized
in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does
not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future
events or otherwise.